Limited Effectiveness in Early Human Clinical Experience with Pulsed Electrical Field Ablation.

Autor:	Rouhezamin MR; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts. Electronic address: mrouhezamin@mgh.harvard.edu., Fintelmann FJ; Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Huang AJ; Department of Radiology, Division of Musculoskeletal Imaging and Intervention, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Arellano RS; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Smolinski-Zhao S; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Patel DM; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Wehrenberg-Klee EP; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts., Uppot RN; Department of Radiology, Division of Interventional Radiology, Massachusetts General Hospital Boston & Harvard Medical School, Boston, Massachusetts.
Jazyk:	angličtina
Zdroj:	Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.
DOI:	10.1016/j.jvir.2024.10.033
Abstrakt:	Purpose: To evaluate oncological outcomes, abscopal effect, and adverse events (AEs) of pulsed electrical field (PEF) ablation of tumors in the chest, abdomen, and pelvis. Materials and Methods: PEF ablations performed at an academic medical center between May 2023 and January 2024 were retrospectively analyzed. Eleven patients (4 males and 7 females; age, 58 years ± 19) underwent 11 PEF sessions targeting 13 tumors (lung metastasis from solitary fibrous tumor [n = 3] and colorectal carcinoma (CA) [n = 1], osteosarcoma pleural metastases [n = 2], hepatocellular CA [n = 2], liver metastasis from colorectal CA [n = 1] and leiomyosarcoma [n = 1], metastatic melanoma to the pancreas [n = 1], metastatic retroperitoneal lymph node from endometrial CA [n = 1], and recurrence of endometrial CA in the vaginal cuff [n = 1]) with the goal of complete coverage (n = 11/13) or debulking (n = 2/13). The mean tumor diameter was 1.9 cm (SD ± 1.0; range, 0.4-3.3 cm). Cross-sectional imaging follow-up was 5.3 months (SD ± 2.2; range, 1.9-7.9 months). Oncological outcomes, abscopal effect, and AEs categorized according to the Society of Interventional Radiology (SIR) guidelines were analyzed. Results: Of 11 tumors that underwent ablation for complete coverage, complete coverage was achieved for 1 (9%), and residual was detected in 9 (81%). Ten (91%) of 11 patients showed either residual, local, or distant progression within a median of 3 months. No abscopal effect was observed. There were 2 mild and 2 severe AEs. Conclusions: PEF ablation showed a low rate of complete coverage (9%) and a high rate (91%) of residual, local, or distant progression. No abscopal effect was observed within a median of 5.1 months after the ablation. (Copyright © 2024 SIR. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu